Nitazene Test Strips: Analogue Coverage and Caffeine Interference

A test strip that detects several nitazenes should not be described as a universal test for the class. The useful questions are which compounds were challenged, at what concentrations, in which mixtures, and under which reading conditions.

Drug-solution testing also needs to be distinguished from biological testing. A limit measured in a prepared drug solution is not a blood or urine detection limit, and it cannot be compared directly with a postmortem concentration to decide whether a strip should have detected an exposure.

What the experimental evaluation found

Marland, Nisbet, and Nic Daéid evaluated a nitazene immunoassay strip against 36 nitazene analogues and 93 other drugs or cutting agents. The strips detected 28 of 36 analogues, with detection limits ranging from 250 ng/mL to 100 µg/mL. Eight analogues were missed. Authentic seized heroin samples produced false positives associated with caffeine above 300 µg/mL. The study examined particular strip lots and conditions. Peer-reviewed experimental study, August 9, 2025; full-text source, DOI: 10.1186/s12954-025-01287-9.

These results demonstrate compound-dependent response and a specific interference problem. They do not establish the sensitivity or specificity of every strip sold under a nitazene label, nor the probability that a particular street sample contains a nitazene after a positive result.

Class coverage should be an explicit table

A laboratory or drug-checking program assessing a device should maintain an analogue-by-analogue record of tested concentrations, observed responses, lot numbers, and result-reading criteria. A single manufacturer threshold can conceal major differences among compounds.

Separate an analogue that was not examined from one examined without detection. Both limit the scope of a negative claim, but they are not the same evidence. When a new analogue emerges locally, its response should not be assumed from similarity of spelling or chemical family.

Record ambiguous and invalid results rather than forcing every strip into positive or negative. Reader disagreement is part of the performance question, especially when faint visual lines are involved.

Mixtures and preparation change the question

Testing a pure reference solution establishes something narrower than testing an authentic mixture. For actual samples, document what portion was selected, how it was prepared, and whether the tested material could represent the whole item. Do not present a preparation-specific result as proof of uniform composition throughout a package.

When dilution is part of a validated procedure, its consequences need to be assessed for both the target and potential interferents. Reducing an interferent can also reduce the target. A procedure intended to address one false-positive mechanism needs evidence that it does not create an unacceptable false-negative problem.

Those are validation questions for controlled laboratory assessment. An improvised preparation cannot be assumed to make an unregulated product safe.

Confirmation should answer identity independently

For evidentiary use, a presumptive strip result should be followed by an appropriately validated identification procedure capable of distinguishing the relevant compounds. Document the relationship between the screened material and the material submitted for confirmation.

A negative confirmation warrants investigation of sample selection, preparation, sensitivity, and specificity. It should not automatically be labeled proof that the strip was defective. Similarly, a positive confirmation for one analogue does not establish a strip's performance for all others.

The strongest report states the device and lot, procedure, result category, known coverage, and confirmatory findings. It avoids converting either a positive strip into a dose estimate or a negative strip into a safety guarantee. See also confirmatory drug testing.